Literature DB >> 2919906

Continued assessment of the combined Collis-Nissen operation.

M C Stirling1, M B Orringer.   

Abstract

The combined Collis-Nissen operation has been performed in 353 patients. Forty-five percent had reflux esophagitis without stricture; 20%, peptic stricture; 72%, a sliding hiatal hernia; 17%, a paraesophageal hernia; 21%, previous antireflux operation; 15%, esophageal spasm; 8%, scleroderma; and 32%, marked obesity. There were 4 postoperative deaths (mortality rate, 1.1%). Complications occurred in 28 patients (8%) and included wound infection (2.2%), esophageal or gastroplasty tube leak (1.7%), bleeding (1.1%), splenic injury, gastric atony, and crural repair dehiscence (each less than 1%). Follow-up includes personal interview, esophageal manometry, and standard acid reflux testing. The average length of follow-up for 261 patients (74%) followed at least 12 months is 43.8 months. Fifty-eight percent have been followed at least 36 months; 41%, 48 months; and 29%, 60 months or longer. Subjectively, in these 261 patients, reflux has been eliminated in 75%, is mild in 11%, is moderate in 9%, and is severe in 5%. Eight percent have postthoracotomy pain; 3%, early satiety ("bloats"); and 1%, postvagotomy diarrhea. Seventeen percent require either periodic or regular esophageal dilations for dysphagia. Objectively, intraesophageal pH studies show good reflux control in 91% and poor reflux control in 9%. Twenty-six patients (10%) have required reoperation for recurrent reflux or dysphagia. These results substantiate satisfactory reflux control using the Collis-Nissen operation in patients at risk for recurrence after standard repairs, but also emphasize that, like other antireflux procedures, the Collis-Nissen operation is not without some degree of postoperative adverse symptoms.

Entities:  

Mesh:

Year:  1989        PMID: 2919906     DOI: 10.1016/0003-4975(89)90274-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  9 in total

1.  Outcomes after esophagectomy in patients with prior antireflux or hiatal hernia surgery.

Authors:  Andrew C Chang; Julia S Lee; Konrad T Sawicki; Allan Pickens; Mark B Orringer
Journal:  Ann Thorac Surg       Date:  2010-04       Impact factor: 4.330

Review 2.  The quality of life following antireflux surgery.

Authors:  C E Pope
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

3.  Collis-Nissen fundoplication using a computer-powered right angle linear cutting stapler in children.

Authors:  Tsubasa Takahashi; Tadaharu Okazaki; Akihiro Shimotakahara; Geoffrey J Lane; Atsuyuki Yamataka
Journal:  Pediatr Surg Int       Date:  2009-11       Impact factor: 1.827

4.  Contemporary management of paraesophaegeal hernias: establishing a European expert consensus.

Authors:  E M Bonrath; T P Grantcharov
Journal:  Surg Endosc       Date:  2014-11-01       Impact factor: 4.584

5.  Collis-Nissen gastroplasty for shortened esophagus: long-term evaluation.

Authors:  J D Richardson; R L Richardson
Journal:  Ann Surg       Date:  1998-05       Impact factor: 12.969

6.  Roux-en-Y reconstruction is superior to redo fundoplication in a subset of patients with failed antireflux surgery.

Authors:  Sumeet K Mittal; András Légner; Kazuto Tsuboi; Arpad Juhasz; Lokesh Bathla; Tommy H Lee
Journal:  Surg Endosc       Date:  2012-10-06       Impact factor: 4.584

Review 7.  The short esophagus: pathophysiology, incidence, presentation, and treatment in the era of laparoscopic antireflux surgery.

Authors:  K D Horvath; L L Swanstrom; B A Jobe
Journal:  Ann Surg       Date:  2000-11       Impact factor: 12.969

8.  Transthoracic Collis-Nissen repair for massive type IV paraesophageal hernia.

Authors:  Hideki Itano; Shiroh Okamoto; Kanji Kodama; Naokatsu Horita
Journal:  Gen Thorac Cardiovasc Surg       Date:  2008-09-13

9.  Short esophagus: how much length can we get?

Authors:  Victor Bochkarev; Yong Kwon Lee; Michelle Vitamvas; Dmitry Oleynikov
Journal:  Surg Endosc       Date:  2008-06-14       Impact factor: 4.584

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.